Recognized clinical trial innovations advocate to lead expansion of Cytel's adaptive trial design and implementation business CAMBRIDGE, Mass., May 14
CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Cytel Inc., a leading provider of
clinical trial design services and specialized statistical software, today
announced the appointment of Judith Quinlan as Vice President, Adaptive
Trials.
Judith Quinlan brings over twenty years of statistical experience to the
Cytel team. Prior to joining Cytel Judith spent 10 years with GSK, most
recently as Statistics Director for biopharmaceuticals, and previously as
Statistics Director for Neurology and GI. Throughout the last seven years
she's focused on bridging the gap between new clinical research concepts and
the challenging practicalities of conducting complex trials.
"Judith Quinlan has been a persistent and persuasive proponent of adaptive
clinical trials both at GSK, and through her work with the PhRMA Working Group
on Adaptive Designs (ADWG). This is helping pave the way toward the wide
acceptance of innovative, flexible clinical study approaches. Judith combines
clinical theory and practice with a strategic business perspective on Clinical
Development Programs. We are very pleased, indeed, to have Judith on board,"
said Cytel's CEO, Ranganath Nayak.
In her new role, Judith Quinlan will guide Cytel's adaptive trial design
and implementation offerings, leveraging her previous successes in managing
cross-functional clinical research teams to drive more productive planning and
implementation of early stage and confirmatory trials. In addition to
overseeing Cytel's flourishing adaptive study efforts, Judith will continue
her advocacy and education work as an active member of the PhRMA Working Group
on Adaptive Designs.
A popular speaker on adaptive trial design and operations, Judith Quinlan
has co-authored articles on numerous clinical research-related topics. Judith
has published in such prestigious journals as Pharmacotherapy and
Computational Statistics, and she co-authored with Wyeth's Mike Krams the
influential PhRMA group's paper on "Implementing Adaptive Designs: Logistical
and Operational Issues."
About Cytel
Cytel Inc. is a leading provider of clinical trial design services and
specialized statistical software for the biopharmaceutical, medical device,
academic, and government research markets. Cytel's East(R) system is used by
biostatisticians and clinicians at hundreds of companies, throughout academia
and by regulators to design, simulate and monitor group sequential and
adaptive clinical trials. Cytel provides trial sponsors with innovative tools,
training, and consultation to increase process efficiencies and reduce
development costs.
SOURCE Cytel Inc.
